Hmm. Still looking for the markers that can help distinguish aggressive from indolent CTCL, and PTCL from MF.
Michi Shinohara
JAK2 fusions in cutaneous T-cell lymphomas are present in both aggressive and indolent disease, including patients with early-stage mycosis fungoides and CD30-positive lymphoproliferative disorders.
ja.ma/4pRtfof
